Managing Mutations in Non-Small Cell Lung Cancer

Joshua Sabari, MD, provides a breakdown of advanced non-small cell lung cancer (NSCLC) and its actionable mutations.

Three medical experts highlight unmet needs they routinely run into while treating patients with NSCLC.

Alexander Spira, MD, PhD, FACP provides an overview of molecular testing in NSCLC.

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers.

Martin Dietrich, MD, PhD, explains what KRAS G12C mutations in NSCLC are and how common they are within the NSCLC landscape.

Dr Sabari highlights typical outcomes for patients with NSCLC vs KRAS G12C-mutated NSCLC, as well as challenges associated with targeted treatments.

Alexander Spira, MD, PhD, FACP, and Joshua Sabari, MD, detail possible therapeutic options for KRAS-mutated NSCLC, focusing on adagrasib and treating brain metastases.

Dr Dietrich discusses patients acquiring and providers managing resistance to KRAS inhibition.

Drs Sabari and Spira comment on the use KRAS inhibitors in both frontline and combination therapies.

Three medical professionals recommend educational needs for both payers and providers within the NSCLC treatment landscape.

Our experts conclude with their final thoughts on the future of NSCLC treatment.